ECV and T2 relaxation time did not change in both study groups.<h4>Conclusion</h4>This study demonstrates that 12 months of dapagliflozin reduces IL-1B mediated systemic inflammation but affect cardiac fibrosis in T2D.<h4>Clinical trialgov registration</h4>NCT03782259. This evidence concerns the gene IL1B and type 2 diabetes mellitus.